Announced details
Medical, pharmaceutical and cosmetics applications
A joint patent applicant for the 24-position disubstituted cholesterol glycoside. The ownership ratio is 50% for IVY COSMETICS CORPORATION and 50% for Kogakuin University Educational Foundation. The parties have agreed that IVY COSMETICS CORPORATION will handle the procedures for obtaining and maintaining the patent rights.
Educational corporation. Details of its location, representative, capital and year of establishment, as well as its business activities, are not disclosed.
International application number PCT/JP2025/032596, patent application number Japanese Patent Application No. 2026-548862, patent term valid through 17 September 2045 (a system allows extensions of up to 5 years for pharmaceuticals)
The impact on the Company's performance is currently undetermined. Because licensing for pharmaceutical applications would require a long period, the Company intends to pursue milestone-based agreements.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | 24-position disubstituted cholesterol glycoside, and an antitumor agent containing the compound as its active ingredient |
| Counterparty | Kogakuin University Educational Foundation |
| Counterparty overview | Educational corporation. Details of its location, representative, capital and year of establishment, as well as its business activities, are not disclosed. |
| Relationship with the Company | A joint patent applicant for the 24-position disubstituted cholesterol glycoside. The ownership ratio is 50% for IVY COSMETICS CORPORATION and 50% for Kogakuin University Educational Foundation. The parties have agreed that IVY COSMETICS CORPORATION will handle the procedures for obtaining and maintaining the patent rights. |
| Applicable area | Medical, pharmaceutical and cosmetics applications |
| Registration number and expiry date | International application number PCT/JP2025/032596, patent application number Japanese Patent Application No. 2026-548862, patent term valid through 17 September 2045 (a system allows extensions of up to 5 years for pharmaceuticals) |
| Impact on Business Performance | The impact on the Company's performance is currently undetermined. Because licensing for pharmaceutical applications would require a long period, the Company intends to pursue milestone-based agreements. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because a novel compound was discovered, isolated and structurally determined from Plumeria rubra as a byproduct of cosmetic development research.